RT期刊文章SR电子T1初始双oral combination therapy in inoperable chronic thromboembolic pulmonary hypertension (CTEPH) JF European Respiratory Journal JO Eur Respir J FD European Respiratory Society SP PA3053 DO 10.1183/13993003.congress-2018.PA3053 VO 52 IS suppl 62 A1 Gabrielly, Michael A1 Bourlier, Delphine A1 Taniguchi, Yu A1 Jevnikar, Mitja A1 Sekine, Ayumi A1 Boucly, Athénaïs A1 Jutant, Etienne-Marie A1 Parent, Florence A1 Savale, Laurent A1 Montani, David A1 Simonneau, Gerald A1 Humbert, Marc A1 Sitbon, Olivier A1 Jais, Xavier YR 2018 UL //www.qdcxjkg.com/content/52/suppl_62/PA3053.abstract AB There is no data on initial dual oral combination therapy in patients with inoperable CTEPH. The aim of our study was to evaluate the efficacy and safety of different regimen of dual combination of oral PAH drugs initiated in this population.A retrospective analysis was carried out between 2007 and 2017 in 139 consecutive patients with inoperable CTEPH initiated with a combination of endothelin-receptor antagonists (ERAs) with riociguat (RIO) or PDE-5 inhibitor.Results: Mean age was 63±13 years (48% males). ERAs were combined with sildenafil (SIL, n=72), tadalafil (TAD, n=40) or RIO (n=27). In the 117 patients re-evaluated after 4 months (median), there were significant improvements in functional class (class I-II 17% to 39%, p<0.001), 6-min walk distance (307±116 to 346±126 m, p<0.001), mean PAP (52±10 to 45±10 mmHg, p<0.001) and pulmonary vascular resistance (PVR) (13.2±4.6 to 7.8±3.3 WU, p<0.001). Dual combination therapy was well tolerated in all patients. The combination of ERAs with RIO or TAD led to greater reduction in PVR than combination of SIL with an ERA (Table). View this table:Conclusion: Initial dual oral combination therapy with ERA and drugs targeting NO pathway improves clinical status, exercise capacity and haemodynamics in patients with inoperable CTEPH, similar to that observed in PAH. The combination of ERAs with RIO or TAD was associated with a significantly greater reduction in PVR compared with SIL and an ERA.FootnotesCite this article as: European Respiratory Journal 2018 52: Suppl. 62, PA3053.This is an ERS International Congress abstract. No full-text version is available. Further material to accompany this abstract may be available at www.ers-education.org (ERS member access only).